World Health Organization (WHO) group 1 pulmonary arterial hypertension (PAH) is a rare but important disorder that narrows pulmonary arterioles and leads to increased pulmonary vascular resistance, right ventricular failure, and death. The diagnosis of PAH requires demonstration of precapillary pulmonary hypertension (PH), defined by a mean pulmonary artery pressure > 20 mm Hg, pulmonary artery wedge pressure (PAWP) ≤ 15 mm Hg, and pulmonary vascular resistance (PVR) > 3 Wood units (WU) not attributable to other disorders. The current classification of group 1 PAH includes seven subclasses (see PAH clinical classification in the review by Beshay et al. in this issue).
Over the past six decades, US investigators occasionally recognized families with multiple members diagnosed with PAH. In 1987, the first registry of US patients diagnosed with what was then called “primary pulmonary hypertension" (PPH) identified more than one affected family member in 13 of 187 (6%) patients with PPH.1 Two decades later, investigators for the Registry to Evaluate Early and Long-term PAH Disease Management (REVEAL) identified 97 of 1,742 (6%) patients with diagnostic features of PPH who had more than one family member diagnosed with PAH.2,3 Neither the National Institutes of Health PPH Registry nor REVEAL investigators used genetic tests to identify heritable PAH (HPAH) or heritable pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis (HPVOD/PCH). Genetic testing can identify HPAH and HPVOD/PCH in patients when the family history does not provide evidence of heritable pulmonary hypertension.
In 2020, investigators for the United States Pulmonary Hypertension Scientific Registry (USPHSR) provided data from the first US PAH patient registry to include genetic information.4 Genetic testing identified pathogenic or suspected pathogenic variants in 67 of 499 (13%) USPHSR participants and reclassified 40 of 218 (18%) patients diagnosed with idiopathic PAH (IPAH) and 13 of 256 (5%) patients diagnosed with associated PAH (APAH) to HPAH.
Physicians recognized HPAH (formerly familial PPH) before molecular causes of HPAH were discovered. In 1954, David Dresdale, MD, described a mother, sister, and son who displayed characteristic features of PPH.5 Thirty years later, Jim Loyd, MD, reported that autosomal dominant inheritance characterized familial PPH.6 In addition, Dr. Loyd described incomplete penetrance when he observed that not all obligate carriers of the causative gene mutation developed PPH. Other investigators suggested that many sporadic (idiopathic) cases of PPH were inherited,7,8 and in 2001, John Newman, MD, reported a common pathogenic mutation in several members of a multigeneration family that already had 12 members who were previously diagnosed with sporadic (idiopathic) PPH.9
Physicians identified other HPAH phenotypes and inheritance patterns. In 1972, Erik Trell, MD, described patients with PAH and hereditary hemorrhagic telangiectasia (HHT).10 Once again, a pattern of autosomal dominant inheritance was present, and penetrance was incomplete. In 1988, David Langleben, MD, identified a family affected by pulmonary capillary hemangiomatosis (PCH).11 In this case, the autosomal recessive inheritance pattern and complete penetrance of PCH differed from familial PPH even though the two disorders shared many clinical features.
Discoveries of pathogenic gene mutations followed these seminal clinical observations. In 2000, two independent teams of investigators identified mutations in BMPR2, a gene that encodes bone morphogenetic protein receptor II, as a cause of familial PPH.12,13 Within months, another team showed that many patients with sporadic (idiopathic) PPH carried pathogenic BMPR2 mutations.14 One year later, Richard Trembath, FRCP, reported that mutations in the gene encoding activin receptor-like kinase 1 (ALK1) caused PAH in patients with HHT.15 Discoveries of additional genes with mutations that caused HPAH followed over the next two decades (Figure 1).16 Although defects in several molecular pathways underlie HPAH, many of the genes implicated caused defects in the transforming growth factor beta pathway.17
Recently, members of the genetics task force of the 6th World Symposium on Pulmonary Hypertension identified 17 genes with evidence of harboring mutations that cause PAH. These causal genes encode a variety of proteins that affect pulmonary vascular structure and function (Table 1).16 Pathogenic mutations in BMPR2 are the most common cause of HPAH in both adults and children.4,18,19 However, the nature of causal gene mutations found in children with PAH differs significantly from the nature of those found in adults with PAH.18 De novo mutations, those not inherited from parents, are more likely to cause PAH in children than adults. Furthermore, the prevalence of genes with causal mutations identified in children with PAH differs significantly from the prevalence of causal gene mutations identified in adults with PAH. For example, mutations in TBX4, a transcription factor in the T-box gene family that modulates limb and lung development, are found more commonly in children than adults with PAH.20
|BMPR2||15.3||PAH||Autosomal dominant with incomplete penetrance|
|TBX4||1.3||PAH||Autosomal dominant with incomplete
More common in children
|KCNK3||<1.0||PAH||Autosomal dominant with incomplete penetrance|
|GDF2||<1.0||PAH||Autosomal dominant with incomplete penetrance|
|KLF2||<1.0||PAH||Autosomal dominant with incomplete penetrance|
|SMAD4||<1.0||PAH||Autosomal dominant with incomplete penetrance|
|ATP13A3||1.1||PAH||Autosomal dominant with incomplete penetrance|
|BMPR1B||<1.0||PAH||Autosomal dominant with incomplete penetrance|
|KCNA5||<1.0||PAH||Autosomal dominant with incomplete penetrance|
|SMAD1||<1.0||PAH||Autosomal dominant with incomplete penetrance|
|SMAD9||<1.0||PAH||Autosomal dominant with incomplete penetrance|
|SOX17||<1.0||PAH||Autosomal dominant with incomplete penetrance|
|AQP||<1.0||PAH||Autosomal dominant with incomplete penetrance|
|CAV1||<1.0||PAH||Autosomal dominant with incomplete penetrance|
|ACVRL1||<1.0||HHT||Autosomal dominant with incomplete penetrance|
|ENG||<1.0||HHT||Autosomal dominant with incomplete penetrance|
|EIF2AK4||<1.0||PVOD, PCH||Autosomal recessive with complete penetrance|
Discoveries of gene mutations that cause PAH and advances in molecular diagnostic testing permit clinicians to use genetic tests to identify which patients diagnosed with PAH have HPAH; furthermore, they allow clinicians to offer genetic counseling and testing to family members when a pathogenic mutation is found.
An offer of genetic counseling (Figure 2) is the first step for patients diagnosed with IPAH or FPAH and for those diagnosed with idiopathic or familial PAH with overt features of venous/capillary involvement. Patients in other PAH subgroups—including PAH associated with drugs, a connective tissue disease, or congenital heart disease—may also benefit from genetic counseling and testing.21
The purpose of genetic counseling is to inform the patient about HPAH and disclose the risks and benefits of genetic testing (Table 2). Potential benefits of genetic testing include informed decisions about reproduction and facilitation of early diagnosis and treatment of family members who develop HPAH. Potential risks of genetic testing include anxiety for family members who carry a pathogenic mutation and feelings of guilt in family members who do not carry a mutation.16,22 In the United States, genetic counselors should address the Genetic Information Nondiscrimination Act of 2008,23 which protects employment and health insurance but does not protect life or long-term disability insurance.
|Describe disease characteristics, mutation detection techniques, and the inheritance pattern of disease transmission.|
|Describe potential implications of genetic test results for the patient.|
|Describe implications and possible consequences for the patient’s family members.|
|Describe prevention and treatment possibilities.|
|Obtain informed consent for genetic testing.|
|Provide individual consultation for asymptomatic high-risk relatives.|
Experts recommend that family members who are diagnosed with PAH, the probands, undergo testing for pathogenic mutations in genes known to cause HPAH before unaffected family members are tested.16 Genetic testing of family members is unnecessary if a pathogenic mutation cannot be identified in the proband. Patients can inform their families when a genetic test suggests HPAH so that other family members can seek genetic counseling and testing. Guideline authors recommend annual evaluations for asymptomatic family members whose mutation status remains unknown or for asymptomatic carriers of pathogenic mutations.24, 25, 26
Genetic tests may include a gene panel, which analyzes multiple genes at once, or whole exome sequencing, which examines all gene-coding regions. Gene panels are the preferred initial test for mutations commonly responsible for HPAH. Next-generation sequencing (NGS) gene panels provide the most rapid turnaround time (weeks), and NGS gene panel tests are most likely to be covered by insurance. NGS panels for PAH may not all examine the same genes. For example, the current PAH NGS panel at Associated Regional and University Pathologists laboratories examines ACVRL1, BMPR2, CAV1, EIF2AK4, KCNA5, KCNK3, and SMAD9 (with the possible addition of TBX4 next year), but other expanded PAH gene panels examine up to 14 additional genes.21
If gene panel testing of a PAH patient’s DNA identifies a pathogenic mutation, then family members can undergo a lower-cost targeted genetic test for the specific mutation. Conversely, if pathogenic mutations are not identified in a PAH gene panel, then whole exome sequencing may be ordered if the clinical suspicion for HPAH remains high.
The complexity of clinical genetic tests for HPAH warrants interpretation by a board-certified clinical molecular geneticist or molecular genetic pathologist. Reports of genetic tests for HPAH identify mutations as “pathogenic,” “likely pathogenic,” “uncertain significance,” “likely benign,” and “benign” according to standards and guidelines of the American College of Medical Genetics and Genomics.27 As with all genetic tests, interpretation may differ and require additional counseling and consultation.28
Post-test genetic counseling is essential for patients who undergo tests to detect and characterize HPAH. Genetic test results are used to characterize an individual family member’s lifetime risk of developing PAH and to identify at-risk members of a family. For example, a family member who does not carry a disease-causing BMPR2 mutation has the same risk as the general population (ie, about one chance in a million) of developing IPAH. In contrast, a first-order relative who carries a disease-causing BMPR2 mutation has approximately one chance in five of developing PAH. Furthermore, available data suggest that the lifetime risk of developing PAH is approximately 14% for men and 42% for women who carry a pathogenic BMPR2 mutation.29
Careful clinical observations, basic molecular discoveries, and advances in laboratory technology have made genetic counseling and testing possible for patients diagnosed with group 1 PAH. Genetic counseling and testing offer PAH patients with other affected family members, those diagnosed with IPAH, and those with familial or idiopathic PVOD/PCH the opportunity to plan their families and avoid the tragedy of undiagnosed and untreated PAH in other family members.
The author has completed and submitted the Methodist DeBakey Cardiovascular Journal Conflict of Interest Statement and none were reported.
Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med. 1987 Aug 1; 107(2): 216–223. doi: https://doi.org/10.7326/0003-4819-107-2-216.
Badesch DB, Raskob GE, Elliott CG, et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest. 2010 Feb; 137(2): 376–387. doi: https://doi.org/10.1378/chest.09-1140.
McGoon MD, Miller DP. REVEAL: a contemporary US pulmonary arterial hypertension registry. Eur Respir Rev. 2012 Mar 1; 21(123): 8–18. doi: https://doi.org/10.1183/09059180.00008211.
Badlam JB, Badesch DB, Austin ED, et al. United States pulmonary hypertension scientific registry: baseline characteristics. Chest. 2021 Jan; 159(1): 311–327. doi: https://doi.org/10.1016/j.chest.2020.07.088.
Dresdale DT, Michtom RJ, Schultz M. Recent studies in primary pulmonary hypertension, including pharmacodynamic observations on pulmonary vascular resistance. Bull N Y Acad Med. 1954 Mar; 30(3): 195–207.
Loyd JE, Primm RK, Newman JH. Familial primary pulmonary hypertension: clinical patterns. Am Rev Respir Dis. 1984 Jan; 129(1): 194–197. doi: https://doi.org/10.1164/arrd.19126.96.36.199.
Elliott G, Alexander G, Leppert M, Yeates S, Kerber R. Coancestry in apparently sporadic primary pulmonary hypertension. Chest. 1995 Oct; 108: 973–977. doi: https://doi.org/10.1378/chest.108.4.973.
Newman JH, Wheeler L, Lane KB, et al. Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred. N Engl J Med. 2001 Aug 2; 345(5): 319–24. doi: https://doi.org/10.1056/NEJM200108023450502.
Trell E, Johansson BW, Linell F, Ripa J. Familial pulmonary hypertension and multiple abnormalities of large systemic arteries in Osler’s disease. Am J Med. 1972 Jul; 53(1): 50–63. doi: https://doi.org/10.1016/0002-9343(72)90115-5.
Langleben D, Heneghan JM, Batten AP, et al. Familial pulmonary capillary hemangiomatosis resulting in primary pulmonary hypertension. Ann Intern Med. 1988 Jul 15; 109(2): 106–109. doi: https://doi.org/10.7326/0003-4819-109-2-106.
Deng Z, Morse JH, Slager SL, et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet. 2000 Sep; 67(3): 737–744. doi: https://doi.org/10.1086/303059.
Lane KB, Machado RD, Pauciulo MW, et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. The international PPH consortium. Nat Genet. 2000 Sep; 26(1): 81–84. doi: https://doi.org/10.1038/79226.
Thomson JR, Machado RD, Pauciulo MW, et al. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family. J Med Genet. 2000 Oct; 37(10): 741–745. doi: https://doi.org/10.1136/jmg.37.10.741.
Trembath RC, Thomson JR, Machado RD, et al. Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med. 2001 August 2, 2001; 345(5): 325–334. doi: https://doi.org/10.1056/NEJM200108023450503.
Morrell NW, Aldred MA, Chung WK, et al. Genetics and genomics of pulmonary arterial hypertension. Eur Respir J. 2019 Jan; 53(1). doi: https://doi.org/10.1183/13993003.01899-2018.
Machado RD, Southgate L, Eichstaedt CA, et al. Pulmonary arterial hypertension: a current perspective on established and emerging molecular genetic defects. Hum Mutat. 2015 Dec; 36(12): 1113–1127. doi: https://doi.org/10.1002/humu.22904.
Welch CL, Chung WK. Genetics and other omics in pediatric pulmonary arterial hypertension. Chest. 2020 May; 157(5): 1287–1295. doi: https://doi.org/10.1016/j.chest.2020.01.013.
Graf S, Haimel M, Bleda M, et al. Identification of rare sequence variation underlying heritable pulmonary arterial hypertension. Nat Commun. 2018 Apr 12; 9(1): 1416. doi: https://doi.org/10.1038/s41467-018-03672-4.
Zhu N, Gonzaga-Jauregui C, Welch CL, et al. Exome sequencing in children with pulmonary arterial hypertension demonstrates differences compared with adults. Circ Genom Precis Med. 2018 Apr; 11(4): e001887. doi: https://doi.org/10.1161/CIRCGEN.117.001887.
Castano JAT, Hernandez-Gonzalez I, Gallego N, et al. Customized massive parallel sequencing panel for diagnosis of pulmonary arterial hypertension. Genes (Basel). 2020 Sep 30; 11(10). doi: https://doi.org/10.3390/genes11101158.
Girerd B, Montani D, Jais X, et al. Genetic counselling in a national referral centre for pulmonary hypertension. Eur Respir J. 2016 Feb; 47(2): 541–552. doi: https://doi.org/10.1183/13993003.00717-2015.
U.S. Equal Employment Opportunity Commission [Internet]. Washington, DC: EEOC Headquarters; c2021. The Genetic Information Nondiscrimination Act of 2008; 2008 [cited 2021 Jan 25]. Available from: https://www.eeoc.gov/statutes/genetic-information-nondiscrimination-act-2008.
Soubrier F, Chung WK, Machado R, et al. Genetics and genomics of pulmonary arterial hypertension. J Am Coll Cardiol. 2013 Dec 24; 62(25 Suppl): D13–21. doi: https://doi.org/10.1016/j.jacc.2013.10.035.
Abman SH, Hansmann G, Archer SL, et al. Pediatric pulmonary hypertension: guidelines from the American Heart Association and American Thoracic Society. Circulation. 2015 Nov 24; 132(21): 2037–2099. doi: https://doi.org/10.1161/CIR.0000000000000329.
McGoon M, Gutterman D, Steen V, et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004 Jul; 126(1 Suppl): 14S–34S. doi: https://doi.org/10.1378/chest.126.1_suppl.14S.
Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015 May; 17(5): 405–424. doi: https://doi.org/10.1038/gim.2015.30.
SoRelle JA, Gemmell AP, Ross TS. Different interpretations of the same genetic data. Ann Intern Med. 2020 Aug 4; 173(3): 239–240. doi: https://doi.org/10.7326/L20-0192.
Larkin EK, Newman JH, Austin ED, et al. Longitudinal analysis casts doubt on the presence of genetic anticipation in heritable pulmonary arterial hypertension. Am J Respir Crit Care Med. 2012 Nov 1; 186(9): 892–896. doi: https://doi.org/10.1164/rccm.201205-0886OC.